Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ph14060561 http://scihub22266oqcxt.onion/10.3390/ph14060561 34208285!8230766!34208285     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34208285&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmaceuticals+(Basel) 2021 ; 14 (6): ä Nephropedia Template TP {{tp|p=34208285|t=2021. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease |pdf=|usr=}}{{34208285}} gab.com Text Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease JO: Pharmaceuticals (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=34208285 #FOAvip Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore, prevention and treatment of DKD are of utmost importance. Much research has been dedicated to the optimization of DKD treatment. In the last few years, mineralocorticoid receptor antagonists (MRA) have experienced a renaissance in this field with the development of non-steroidal MRA. Steroidal MRA have known cardiorenal benefits, but their use is limited by side effects, especially hyperkalemia. Non-steroidal MRA still block the damaging effects of mineralocorticoid receptor overactivation (extracellular fluid volume expansion, inflammation, fibrosis), but with fewer side effects (hormonal, hyperkalemia) than steroidal MRA. This review article summarizes the current knowledge and newer research conducted on MRA in DKD. Twit Text FOAVip Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease ????Pharmaceuticals (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=34208285 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34208285 #FOAvip English Wikipedia <ref>{{Cite pmid|34208285}}</ref> Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease #MMPMID34208285 Vodosek Hojs N; Bevc S; Ekart R; Piko N; Petreski T; Hojs R Pharmaceuticals (Basel) 2021[Jun]; 14 (6): ä PMID34208285show ga Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore, prevention and treatment of DKD are of utmost importance. Much research has been dedicated to the optimization of DKD treatment. In the last few years, mineralocorticoid receptor antagonists (MRA) have experienced a renaissance in this field with the development of non-steroidal MRA. Steroidal MRA have known cardiorenal benefits, but their use is limited by side effects, especially hyperkalemia. Non-steroidal MRA still block the damaging effects of mineralocorticoid receptor overactivation (extracellular fluid volume expansion, inflammation, fibrosis), but with fewer side effects (hormonal, hyperkalemia) than steroidal MRA. This review article summarizes the current knowledge and newer research conducted on MRA in DKD. äMineralocorticoid Receptor Antagonists in Diabetic Kidney Disease (epmc).pdf DeepDyve Pubget Overpricing